CROSSJECT reported a cash position of €6.3 million for the first half of 2025, with stable R&D investments and increased reimbursements from BARDA. The company made progress towards submitting an Emergency Use Authorization application for ZEPIZURE®. They also secured an €11.3 million extension of R&D funding with the U.S. government.

The operating loss for CROSSJECT in the first half of 2025 was €5.1 million, an improvement from €6.7 million in 2024. This was due to increased reimbursements from BARDA and good control of operating expenses. The net loss for the company was €4.9 million for the first half of 2025.

Assets for CROSSJECT as of June 30, 2025, totaled €31.375 million, with current assets of €15.7 million. Liabilities and Shareholders’ Equity for the same period amounted to €26.675 million, with total assets equalling total liabilities and shareholders’ equity at €31.375 million. The company continues to evaluate financing options for its activities.

Read more at GlobeNewswire: CROSSJECT presents its financial results and key highlights